statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for ROIV
 DateFirmActionFromTo Dec 2021Goldman SachsInitiates Coverage OnBuy Nov 2021HC Wainwright & Co.Initiates Coverage OnBuy Nov 2021SVB LeerinkInitiates Coverage OnOutperform...

Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know

Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) - Analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Roivant Sciences in a research note issued to...

Roivant Sciences Ltd. to Post Q1 2025 Earnings of ($0.25) Per Share, HC Wainwright Forecasts (NASDAQ:ROIV)

Roivant Sciences (NASDAQ:ROIV - Free Report) had its target price increased by HC Wainwright from $17.00 to $18.00 in a research report report published on Wednesday morning, Benzinga reports. The...

Roivant Sciences (NASDAQ:ROIV) Price Target Increased to $18.00 by Analysts at HC Wainwright

Roivant's board of directors has approved a share repurchase program for up to $1.5 billion of the company's common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648...

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) saw unusually large options trading on Tuesday. Stock investors purchased 11,070 call options on the company. This represents an increase of...

Roivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV)

Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure...

Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study

In trading on Tuesday, shares of Roivant Sciences Ltd (ROIV) crossed above their 200 day moving average of 10.55, changing hands as high as 11.26 per share. Roivant Sciences Ltd shares are...

Roivant Sciences Breaks Above 200-Day Moving Average - Bullish for ROIV

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $10.43, but opened at $10.93. Roivant Sciences shares last...

Roivant Sciences (NASDAQ:ROIV) Shares Gap Up to $10.43

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Roivant Sciences to replace Sunrun in the S&P 400 at open on 4/1

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) traded down 4% on Thursday . The stock traded as low as $10.37 and last traded at $10.41. 3,304,999 shares traded hands during mid-day...

Roivant Sciences (NASDAQ:ROIV)  Shares Down 4%

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Volume	66.00
52-Wk High	$13.24
52-Wk Low	$8.25

Period	Estimated	Reported	Surprise	Result
Q4'23	-$0.28	--	--	N/A
Q3'23	-$0.31	$6.03	2051.46%	BEAT
Q2'23	-$0.29	-$0.26	8.77%	BEAT
Q1'23	-$0.28	-$0.23	19.97%	BEAT
Q4'22	-$0.36	-$0.22	39.43%	BEAT

ROIV Roivant Sciences Ltd

About

Feed

News

Sentiment

Earnings

Fundamentals